In this study, patients will be treated with low dose melphalan and 4 doses of HDAA for one cycle only. In total, 9 patients will be enrolled in this study. Bone marrow examination and imaging with PET and/or MRI will be performed 4 weeks from last dose of HDAA.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Non-secretory participants are eligible provided the participant has > 20% bone marrow plasmacytosis OR multiple (≥3) plasmacytomas or lesions on MRI at the time of diagnosis or study enrollment, OR the presence of lesions (≥ 3) on PET/CT scan.
The following is a listing of trial locations that are open and accepting patients.
There are no resources, links or videos to display for this clinical trial.